Kenvue Inc.

Kenvue Inc.

KVUENYSE / NASDAQConsumer DefensiveLarge cap

$19.31-$0.25 (-1.3%)

Last close · Data as of Oct 30, 2026

Market cap
$32.4B
P/E
22.0x
EV / EBITDA
13.4x
Revenue
$15.1B
Net margin
9.7%
ROCE
12.8%

Hidden because the last close is more than three trading days older than the latest prices of its class.

Kenvue Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 30 Oct 2026 close.

1M
Stale
3M
Stale
6M
Stale
1Y
Stale
5Y
Stale
  • Hidden because the last close is more than three trading days older than the latest prices of its class.

52-week range

Day change -$0.25 (-1.3%) from $19.56 to $19.31 · Last close Oct 30, 2026

Best weekday to invest, historically

The same weekly amount in KVUE, bought on each weekday since 2023.

News & filings

What Kenvue filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthOperating margin of 18.0% against a peer median of 5.9%.

Concerns (1)

  • Current assets are 0.96 times current liabilities.
  • Prices are as of 30 Oct 2026; price-based points are paused until newer prices arrive.

Prices to the 30 Oct 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health.

Read moreShow less

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Sector
Consumer Defensive
Shares outstanding
1.93B

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$32.4B
P/E
22.0x
P/B
3.0x
EV / EBITDA
13.4x
EV / Sales
2.6x
P/S
2.1x
52-week high
$19.88
52-week low
$14.24

Profitability

Operating margin
18.0%
Net margin
9.7%
EBITDA margin
19.7%
ROE
13.7%
ROCE
12.8%
ROA
5.4%
Asset turnover
0.56

Growth

Revenue
$15.1B
Revenue growth, 1Y
-2.1%
Revenue CAGR, 3Y
0.4%
Net profit growth, 1Y
42.7%
Free cash flow
$1.7B

Solvency

Current ratio
0.96
Debt / Equity
0.81
Debt / Assets
0.32
CFO / Net profit
1.49
Cash / Market cap
3.3%

Where the revenue went

Of every $100 of FY2025 revenue, $10 was left as net income.

Kenvue Inc. income statement flow, FY2025
Kenvue Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$6.3B
RevenueGross profit$8.8B
Gross profitOperating expenses$6.1B
Gross profitOperating income$2.7B
Operating incomePretax income$2.0B
Operating incomeInterest and other expense$716.0M
Pretax incomeTax and other$529.0M
Pretax incomeNet income$1.5B

Revenue and net profit

Revenue fell 2.1% in FY2025; net profit is the dashed line.

Kenvue Inc. revenue and net profit by fiscal year
Kenvue Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$14.9B$2.1B
FY2023$15.4B$1.7B
FY2024$15.5B$1.0B
FY2025$15.1B$1.5B

Cash flows

FY2025: $2.2B from operations, $1.7B free after investment (dashed).

Kenvue Inc. operating and free cash flow by fiscal year
Kenvue Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$2.5B$2.1B
FY2023$3.2B$2.7B
FY2024$1.8B$1.3B
FY2025$2.2B$1.7B

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$15.1B-2.1%1Y
EBITDA
$3.0B+21.0%1Y
Net profit
$1.5B+42.7%1Y
Cash from operations
$2.2B+24.2%1Y
Free cash flow
$1.7B+29.0%1Y
Revenue CAGR, 3Y
0.4%
Net profit CAGR, 3Y
-10.7%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$15.1B$3.0B$1.5B$1.7B13.7%-2.1%+42.7%

Monthly returns

Month-by-month returns of KVUE across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$27.1B
Liabilities$16.3B
Equity$10.8B
Paid-in capital$16.3B
Retained earnings-$204.0M
Treasury stock$439.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Consumer Defensive companies placed by value, growth and quality; KVUE highlighted.

P/E against peers

KVUE trades at 22.0x earnings against a peer median of 30.8x (a 28% discount).

Not shown (no positive earnings and no EV / Sales): The Estée Lauder Companies Inc., The Kraft Heinz Company.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Kenvue Inc.KVUEthis companyP/E ↓ discount$32.4B22.0x3.0x13.7%13.4x
Archer-Daniels-Midland CompanyADM$40.2B37.3x1.8x4.7%16.1x
The Kroger Co.KR$38.4B37.8x6.5x17.1%10.4x
The Hershey CompanyHSY$37.1B42.0x8.0x19.0%21.6x
Sysco CorporationSYY$35.6B19.4x19.4x99.9%11.8x
Kimberly-Clark CorporationKMB$31.4B15.5x20.9x134.6%12.2x
The Estée Lauder Companies Inc.EL$30.0B—7.8x-29.3%250.3x
The Kraft Heinz CompanyKHC$26.6B-4.6x0.6x-14.0%-12.8x
Bunge Global SABG$25.1B30.8x1.6x5.1%16.2x
Peer median—30.8x7.1x11.1%14.1x

Year-to-date ROI

KVUE since 1 January, against earlier years.

Historical volatility

KVUE's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Kenvue Inc. operating margin by fiscal year
Kenvue Inc. operating margin by fiscal year
DateOperating margin
FY202218.0%
FY202316.1%
FY202417.0%
FY202518.0%
LineFY2025
Cost of revenueCost Of Revenue$6.3B
Gross profitGross Profit$8.8B
Operating expensesOperating Expense$6.1B
Selling, general and administrativeSelling General And Administration$6.1B
Other operating expensesOther Operating Expenses-$11.0M
Total expensesTotal Expenses$12.4B
Pretax incomePretax Income$2.0B

Learn while you research

Academy chapters picked for Kenvue Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Cyclical vs Defensive StocksConsumer staples behave defensively across the business cycle.6 min read
  3. 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  4. 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →